Dectin-2 Binding Antibodies for NF-κB Tumor Immune Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for additional methods to prevent and treat cancer, as most cancer patients fail standard of care therapies, and Dectin-2 activation can elicit a pro-inflammatory immune response that can lead to an anti-tumor immune response.
Innovation Solution
Development of Dectin-2 binding agents comprising immunoglobulin heavy and light chain variable region polypeptides that specifically bind to Dectin-2, either as monomers, homodimers, or heterodimers, to activate Dectin-2 signaling pathways in myeloid cells, thereby enhancing immune response against tumors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard of care therapies are used for cancer treatment, then initial treatment can be provided, but most cancer patients ultimately fail these therapies
Solution Approach 1:
The patent introduces Dectin-2 binding agents as intermediary substances that mediate between the immune system and tumor cells. These agents bind to Dectin-2 receptors on myeloid cells, triggering immune responses that target tumors. This intermediary approach overcomes the limitations of standard therapies by engaging the immune system as a mediator to achieve sustained anti-tumor activity.
Solution Approach 2:
The patent changes the therapeutic parameter from direct anti-tumor action to immune system modulation. By targeting Dectin-2 receptors and activating specific immune pathways (NF-κB, phagocytosis), the treatment transforms the mechanism of action to achieve more durable responses. This parameter change from conventional cytotoxic approaches to immune activation provides prolonged treatment efficacy.
2Reliability
If Dectin-2 binding agents are developed to activate immune response, then anti-tumor immunity can be enhanced, but additional therapeutic options are needed beyond existing treatments
Solution Approach 1:
The Dectin-2 binding agents possess multi-functionality by simultaneously activating multiple immune pathways (NF-κB activation, phagocytic enhancement, pro-inflammatory cytokine production). This universal approach addresses the need for diverse therapeutic options by providing a single agent with multiple mechanisms of anti-tumor action, thereby enhancing adaptability in cancer treatment strategies.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The Dectin-2 binding agents stimulate Dectin-2 expressing cells, enhancing pro-inflammatory cytokine production and phagocytic activity, potentially leading to effective cancer treatment by activating the NF-KB pathway and increasing anti-tumor immune responses.
Implementation Method 1
Activation of the Dectin-2 pathway can elicit a pro-inflammatory immune response in these cells, including activation of the NF-KB pathway and subsequent production of pro-inflammatory cytokines
Implementation Method 2
Activation of the Dectin-2 pathway can elicit a pro-inflammatory immune response in these cells, including activation of the NF-KB pathway and subsequent production of pro-inflammatory cytokines, as well as increased phagocytic activity
Data Source
AI summary
The invention relates to dendritic cell-associated C-type lectin 2 (Dectin-2) binding agents, nucleic acids comprising the inventive binding agents, vectors and cells comprising the inventive nucleic acids, and compositions thereof. The invention also relates to methods of providing the inventive binding agents, methods for treating a disease, disorder, or condition in a mammal, and methods of stimulating an antigen presenting cell.